Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 66.17 and 45.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC AG89.40%2 323
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, IN..233.49%12 349
NEKTAR THERAPEUTICS361.53%8 960
ALKERMES PLC-7.23%8 092
SEATTLE GENETICS, INC.5.57%7 563
QIAGEN NV10.15%7 414
SAGE THERAPEUTICS INC209.50%6 664
IONIS PHARMACEUTICALS INC12.00%6 520
EXACT SCIENCES CORPORATION288.32%6 173
ICON PLC50.96%6 161
UNITED THERAPEUTICS CORPORA..-4.98%5 938
PRA HEALTH SCIENCES INC61.70%5 719
More Results
Financials (€)
Sales 2017 246 M
EBIT 2017 45,7 M
Net income 2017 28,2 M
Debt 2017 103 M
Yield 2017 -
P/E ratio 2017 66,17
P/E ratio 2018 45,42
EV / Sales 2017 8,47x
EV / Sales 2018 6,31x
Capitalization 1 977 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart EVOTEC AG
Duration : Period : Day
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Duration : Period : Week
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders